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Inclusion criteria 
Types of studies:  
All randomised controlled trials of human albumin or 
plasma protein fraction (PPF) administration (albumin/
PPF versus no albumin/PPF, or a crystalloid solution). 
Types of participants: 
Critically ill patients with hypovolaemia, burns or 
hypoproteinaemia. Trials involving patients receiving 
pre-operative volume loading or haemodilution, and 
trials of albumin administration during paracentesis 
were excluded. 
Types of intervention: 
Human albumin solution or plasma protein fraction 
(PPF). 
Types of outcome measures: 
The principal outcome measure was mortality from all 
causes assessed at the end of the follow up period 
scheduled for each trial. 
 
Results 
• 32 trials met the inclusion criteria and reported 
death as an outcome. Sixteen were adequately 
concealed.  
• There were 177 deaths among 1519 trial 
participants.  
• For each patient category the risk of death in the 
albumin treated group was higher than in the 
comparison group.  
• For hypovolaemia the relative risk of death 
following albumin administration was 1.46 (95% 
confidence interval 0.97 to 2.22), for burns the 
relative risk was 2.40 (1.11 to 5.19), and for 
hypoalbuminaemia the relative risk was 1.38 (0.94 
to 2.03). 
• Overall, the risk of death in patients receiving 
albumin was 14% compared to 9% in the control 
groups, an increase in the risk of death of 5% (2% 
to 8%). These data suggest that for every 20 
critically ill patients treated with albumin there is 
one additional death. 
 
Does albumin reduce mortality in critically ill people? 
There is no evidence that albumin administration reduces the risk of death in  
critically ill patients with hypovolaemia, burns or hypoalbuminaemia. 
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Reviewer’s conclusions 
Implications for practice:  
It would seem reasonable to conclude clinicians considering using human albumin in critically ill patients 
should review their policies.  
Implications for research: 
A strong argument could be made that albumin should not be used outside the context of a properly concealed 
and otherwise rigorously conducted randomised controlled trial with mortality as the end point. Until such data 
become available, there is also a case for a review of the licensed indications for albumin use. 
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